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SHORT COMMUNICATION
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Clinical trials have shown the efficacy of interferon (IFN)
alpha in a number of lymphoproliferative diseases and in
solid tumours such as melanoma and renal cancer. Most of
these studies were performed according to classical protocols
of anticancer chemotherapy, using maximal tolerated doses
or doses giving highest serum IFN concentrations. However,
the best results, including a high percentage of complete
remissions, were obtained in hairy cell leukaemia with
relatively low doses of IFN-alpha (3 x 106 units/day or three
times weekly, Flandrin et al., 1986) which give hardly
detectable serum levels (Lodemann et al., 1985). To establish
a rationale for the clinical trial of lower IFN doses, which
are associated with less side-effects, it seems important to
determine the relative biological activities of lower doses of
IFN. We have thus studied three responses specifically
induced in peripheral blood mononuclear cells (PBMC) of
cancer patients by the standard dose of 3 x 106 IU IFN-alpha
and by a tenfold lower dose (0.3 x 106 IU). These responses
were the down-regulation of membrane IFN-alpha receptors,
previously shown to occur in vivo (Billard et al., 1986;
Maxwell et al., 1985), the antiviral state, and (2'-5')
oligoadenylate (2-5A) synthetase activity which is a sensitive
marker of IFN therapy (Schattner et al., 1981; Merritt et al.,
1986).
The study was carried out on six patients with metastatic
renal cell carcinoma, entering a phase IT clinical trial
performed with natural IFN-alpha. This IFN has been
purified from human leukocytes according to the Cantell's
method (Cantell et al., 1981) by one of us (KN). Its specific
activity was about 2 x 106 IUmg- protein. The
characteristics of the patients, who had received no treatment
for four weeks prior to the study, are summarized in Table I.
Differential white cell counts were performed using May-
Table I Clinical characteristics of the patients
at the beginning of the studya
Patient Age/Sex Body weight Metastases
1 63/M 93 Bone
2 59/F 50 Thyroid
lung
3 50/M 60 Lung
lymph nodes
4 58/F 44 Lung
5 63/F 56 Pleura
lung
6 71/F 61 Lung
aNormal heart and bone marrow functions
were among criteria of inclusion into the clinical
trial.
Grunwald-Giemsa stain. PBMC were isolated on Ficoll-
Paque (Pharmacia) gradient. Expression of high affinity cell
surface receptors for IFN-alpha was determined by
Scatchard analysis of specific binding of human recombinant
IFN-alpha-2 labeled with 125I, as previously described
(Aguet & Blanchard, 1981). The 2-SA synthetase activity was
measured by an assay described earlier (Justesen et al., 1980).
Antiviral state was evaluated by an adaptation of the
technique of Levin & Hahn (1981). Briefly, 2 x 106 PBMC
were infected at 37°C for 1 h with vesicular stomatitis virus
(VSV, Indiana strain) at a 0.6 multiplicity of infection. Non-
adsorbed virus was removed by washing three times. Cells
were incubated for 24h, then disrupted by freeze-thawing.
Viral yield was determined by titration on L-929 mouse cells.
Serum IFN levels were measured in a cytopathic effect
inhibition assay using human Wish cells challenged with
VSV (Wietzerbin et al., 1984). Titres were standardized to the
NIH human leukocyte IFN No. GA-902-530. All
measurements were performed immediately before and at
different times after a first i.m. injection of 0.3 x 106 IU IFN-
alpha and after a second dose of 3 x 106 IU given one week
later.
Figure 1 shows typical results obtained from patient No. 2.
Before treatment, PBMC exhibited about 1,900 IFN-alpha
receptors/cell, with affinity constant (Kd) of 2.4 x O01- M.
The number of receptor sites/cell decreased markedly
without affinity changes within 24h after the first dose of
0.3 x 106 IU, resulting in a receptor down-regulation of about
70% at 48 h. This latter was then reversed, resulting in a
complete recovery of the initial number of receptors. An 80%
decrease in the number of receptors/cell was induced as soon
as 6 h after the 3 x 106 IU dose, as previously observed
(Billiard et al., 1986), increasing gradually after 24 h.
Therefore, the receptor down-regulation was of similar
amplitude with both IFN doses. Measurements of 2-5A
synthetase activity (basic level 0.6 nmol AMP min- 10-7
cells) showed induction within 12 h after injection of
0.3 x 106 IU, with maximal stimulation at 24h. The plateau
value was maintained for an additional 24h to decrease
rapidly thereafter, recovering the pretreatment level by 168 h.
While the rate of induction seemed higher with the dose of
3 x 106 IU, the maximal stimulation of 2-SA synthetase
activity was the same as that obtained with 0.3 x 106 IU. An
antiviral state was induced in PBMC within 24h after each
IFN dose. One thousand-fold inhibition in viral
multiplication was observed after both doses. The antiviral
state remained stable for -48h in both cases then declined
in parallel thereafter.
White cell counts in peripheral blood revealed a marked
lymphopenia as soon as 6 h after injection of each of the two
doses, which was completely reversed by 48 h. On the
contrary, neutrophils did not show any particular pattern of
modification (data not shown).
Similar results were observed with the five other patients
examined (Table TI). Despite individual variations in pre-
treatment values and time-course, the amplitudes of response
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in the six patients to 0.3 x 106 IU IFN were not significantly
different from those measured after the 3 x 106 IU dose.
Serum IFN levels were low, ranging from 0 to
124 IUml-' after injection of 3 x 106 IU IFN. They did not
correlate with the above described biological effects.
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Figure 1 Analysis of the effects of two different doses of IFN-
alpha administered to a renal cancer patient (No. 2) on three
biological responses of PBMC: Down regulation of IFN-alpha
receptors (A), induction of 2-SA synthetase activity (B), and of
antiviral resistance (C), as described in the text. Values observed
after one i.m. injection of 0.3 x 106 IU (-), then after a dose of
3 x 10' IU given one week later (Ol). Number of high-affinity
receptor sites per cell were based on mean of triplicate values of
specific binding, with standard deviation less than 10%. (2-5)A
synthetase activity (nmol AMP min-' 10-7 cells) are mean of
duplicate values, with a standard deviation less than 8%.
Moreover, no serum IFN activity was detected after the
0.3 x 106 IU dose (data not shown).
The patients exhibited moderate flu-like syndrome (fever,
chills, headache particularly) after IFN injection, but no
evident differences could be detected in this effect between
the two doses. To relieve these symptoms, only paracetamol
was given to the patients. No prostaglandin inhibitors such
as aspirin or corticoids were administered.
Our data show that i.m. administrations of 3 x 106 IU
IFN-alpha or of a tenfold lower dose to patients with renal
cancer give similar responses in peripheral leukocytes. This
result does not seem to depend upon a carry-over effect of
the 0.3 x 106 IU dose since in an additional patient the order
of doses was reversed without change in any of the three
biological responses tested. Furthermore, it cannot be merely
attributed to lymphocyte redistribution because the observed
lymphopenia was completely reversed by 48 h while the
biological effects of IFN were still maximal, in agreement
with a previous study of Scott et al. (1983). There were only
slight variations in the rate of induction but not in the extent
of the three effects studied. The down-regulation of IFN-
alpha receptors was found to be quite similar to that
previously reported for peripheral blood cells upon in vivo
treatment with several million units of IFN-alpha (Billard et
al., 1986; Lau et al., 1986; Maxwell et al., 1985). The
observation that the dose of 0.3 x 106 IU is able to induce the
same effect on IFN-receptor interaction, which is the first
step in IFN action, is of great interest. Although its role in
the antitumour effect of IFN remains to be established,
receptor down-regulation is currently thought to reflect the
state of responsiveness to IFN (Billard et al., 1986; Maxwell
et al., 1985).
The enzyme 2-5A synthetase is a biochemical pathway
induced by IFNs and is thought to be involved in their
antiviral action (Lengyel, 1982). Whether this enzyme also
plays a role in other properties of IFN is not known,
although changes in 2-5A synthetase activity were associated
with cell growth and differentiation in different systems (see
Rossi, 1985, for review). Basic levels of the enzyme differed
depending on the patients, and the extents of stimulation
after i.m. administration in the dose range studied here were
in agreement with those previously reported by Lodeman et
al. (1985) and Merritt et al. (1986). However, the range of
dose-response relationship reported by Merritt et al. (1986)
was wider.
We also show that PBMC from cancer patients who were
treated with single doses of IFN-alpha are able to develop a
state of antiviral resistance, even in absence of detectable
serum IFN, and that this antiviral state closely parallels the
induction of 2-5A synthetase by both IFN doses. The
antiviral state, which is easy to measure in circulating
leukocytes, giving reproducible results, seems thus to be a
convenient biological marker of the IFN system, although a
wider range of doses has to be examined.
Previous attempts to use immunological parameters for
testing IFN activity in clinical trials have been unsuccessful,
Table II Comparison of the effects of two different interferon-alpha doses on biological
responses in PBMC from six renal cancer patients
Maximal response
Dose Statistical
Effect (x 106 IU) Daya Amplitudeba significationc
Increase in 2-SA 0.3 1 (1-2) 3.48 (1.83-5.66) P<0.05
synthetase activity 3.0 1 (1-3) 2.96 (2.03-6.38) P< 0.025
Decrease in virus yield 0.3 1 (1-2) 2.14 (1.93-2.20) P<0.025
3.0 1 (1-2) 2.43 (1.88-2.60) P<0.05
Decrease in number 0.3 1 (1-2) 2.56 (1.72-3.23) 0.l>P>0.05
of IFN-a receptors 3.0 1 (1-2) 2.38 (1.54-5.79) 0.1 > P>0.05
aMedian (range); bRatio: maximal effect/pre-treatment values; CComparison of values at
24 h with pretreatment values (non-parametric analysis of variance of Friedman).SIMILAR EFFECTS OF DIFFERENT IFN DOSES 679
particularly on account of the heterogeneity of available
assays (Herberman, 1983). On the contrary, all three IFN
responses tested in the present work provided similar results,
leading to the conclusion that administration of 0.3 x 106 IU
IFN-alpha is able to activate immunocompetent cells in
peripheral blood in the same way as the higher dose of
3 x 106IU, without correlation to serum IFN levels. Once
induced, these responses have their own kinetics, requiring
more than 96 h to be reversed. These results support the use
of markers of the IFN system for monitoring clinical trials
with IFN instead of serum IFN levels.
Our data favour the view that minimal biologically active
doses might be selected to design therapy of human cancer
with IFN, rather than maximal tolerated doses, and that
daily administrations might not be needed. In this respect, it
has recently been reported that such low doses as
0.5 x 106IU IFN-alpha or low frequency protocols were
successfully used in the treatment of hairy cell leukaemia
with reduced side effects (Berneman et al., 1986; Hiuber et al.,
1985; Porzsolt et al., 1985).
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